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Abstract
Objective: It may be possible to thrombolyse ischaemic stroke (IS) patients up to 6 h by using penumbral imaging. We
investigated whether a perfusion CT (CTP) mismatch can help to select patients for thrombolysis up to 6 h.
Methods: A cohort of 254 thrombolysed IS patients was studied. 174 (69%) were thrombolysed at 0–3 h by using non-
contrast CT (NCCT), and 80 (31%) at 3–6 h (35 at 3–4.5 h and 45 at 4.5–6 h) by using CTP mismatch criteria. Symptomatic
intracerebral haemorrhage (SICH), the mortality and the modified Rankin Score (mRS) were assessed at 3 months.
Independent determinants of outcome in patients thrombolysed between 3 and 6 h were identified.
Results: The baseline characteristics were comparable in the two groups. There were no differences in SICH (3% v 4%,
p=0.71), any ICH (7% v 9%, p=0.61), or mortality (16% v 9%, p=0.15) or mRS 0–2 at 3 months (55% v 54%, p=0.96)
between patients thrombolysed at 0–3 h (NCCT only) or at 3–6 h (CTP mismatch). There were no significant differences in
outcome between patients thrombolysed at 3–4.5 h or 4.5–6 h. The NIHSS score was the only independent determinant of
a mRS of 0–2 at 3 months (OR 0.89, 95% CI 0.82–0.97, p=0.007) in patients treated using CTP mismatch criteria beyond 3 h.
Conclusions: The use of a CTP mismatch model may help to guide thrombolysis decisions up to 6 h after IS onset.
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Introduction
Intravenous thrombolytic treatment for ischaemic stroke (IS)
usingarecombinanttissueplasminogenactivator(tPA)within3 hof
symptom onset has been well established by randomised controlled
studies [1], the results of which have been replicated in
observational registries [2]. The European Cooperative Acute
Stroke Study (ECASS) III study has demonstrated that tPA is more
efficaciousthan placebo inthe 3–4.5-h window[3].Results fromthe
updated SITS-ISTR registry of thrombolysed patients support the
benefit of treatment in the 3–4.5-h window, although with odds
lower for a good functional state and higher for symptomatic
intracerebral haemorrhage (SICH) and mortality as compared with
treatment within 0–3 h [4]. A recent pooled analysis of randomised
controlled thrombolysis trials with patients selected by clinical
symptoms and non-contrast CT (NCCT) within 0–6 h found that
the odds of a favourable outcome decreased and those of mortality
rose with increase of the onset-to-treatment time (OTT), and
concluded that patients benefit from tPA when treated up to 4.5 h
[1]. However, within a large cohort of patients there might be some
who still derive benefit from treatment up to 6 h [1].
Penumbral imaging may be an approach with which to select
patients likely to benefit from thrombolysis in an extended time
window [5]. Results from large observational studies suggest that
multimodal MRI-guided thrombolysis between 3 and 6 h has
safety and efficacy outcomes comparable to those of NCCT-based
thrombolysis within 0–3 h [6]. A target MR mismatch profile
associated with the best outcomes has also been suggested [7]. The
use of MRI for patient selection in acute stroke, however, is
frequently limited, reasons including restricted access to hyper-
acute MRI in many hospitals, and established contraindications
such as certain implanted devices, or uncooperative or claustro-
phobic individuals. Perfusion CT (CTP) has much fewer
constraints, and is available on many scanners currently in use.
Interestingly, there have been no published reports of studies in
which patients were selected exclusively with CTP to undergo
intravenous tPA therapy in an extended time window [8].
The hypothesis of this study was that a structured assessment of
CTP in the clinical routine can identify patients with a target
mismatch profile who are likely to benefit from late thrombolysis.
The objective was to compare safety and efficacy outcomes of
intravenous thrombolysis in patients presenting at 3–6 h, assessed
with a simple but structured evaluation of CTP by using the
semiquantitative Alberta Stroke Program Early CT Score
(ASPECTS) scale [9], with those presenting within 0–3 h, assessed
with NCCT.
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Ethics Statement
All patients in this study received treatment according to
standard clinical practice. The routine clinical use of tPA beyond
current licence in selected patients was approved by the King’s
College Hospital Novel Procedures Committee. All participants or
their surrogates provided informed verbal consent, which was
documented in the medical notes as per the institutional Clinical
Governance procedures. The analysis of data collected during the
routine clinical management of patients was in compliance with
the institutional Clinical Governance guidelines to monitor the
safety of thrombolysis.
Patients
Data were prospectively collected and entered into a database
on all consecutive patients with anterior circulation IS who were
thrombolysed according to a standard clinical protocol within 6 h
of symptom onset at a single stroke centre between 2007 and 2009.
Baseline patient characteristics and OTT and arrival-to-treatment
time (ATT) were recorded. The National Institute of Health
Stroke Scale (NIHSS) score was documented by certified assessors
at baseline and at 24 h after thrombolysis [10]. The modified
Rankin Score (mRS) was recorded to characterize the level of
functioning both pre-morbidly and at 3 months post-thrombolysis
[11]. All analyses were done retrospectively on the prospectively
collected dataset.
Imaging
CT examinations were performed on a 16-slice multidetector
scanner (LightSpeed, GE Healthcare, USA). All patients under-
went routine NCCT to exclude haemorrhage and to assess early
ischaemic changes. The negative ordinal ASPECTS scale (range
10-0) was used to evaluate the extent of ischaemic change within
the middle cerebral artery (MCA) territory [9]. CTP was
undertaken immediately following NCCT in IS patients who
presented between 3 and 6 h. Image acquisition was performed as
a 50-sec cine series beginning 5 sec after a power injection
(Medrad Power Injector, Medrad, USA) of 50 ml of a non-ionic
iodinated contrast (Ominpaque 300 mg/mL, GE Healthcare,
UK) at 4 ml/s through a 18–20 gauge antecubital intravenous
catheter. The imaging parameters were 80 kVp, 200 mAs, and a
rotation time of 1 sec. Coverage consisted of two contiguous slices
of 10-mm thickness positioned parallel and superior to the orbital
roof, with the more caudal section at the level of the basal ganglia
and internal capsule. The dynamic perfusion CT source images
were analysed by using a semi-automated postprocessing software
(CT Perfusion 2.6.9, GE Medical Systems, USA) that generated
colour maps of cerebral blood volume (CBV), cerebral blood flow
(CBF) and mean transit time (MTT). The colour scales were set at
0–10 ml/100 g for the CBV, 0–100 ml/100 g/s for the CBF, and
0–15 s for the MTT maps. The arterial and venous inputs were
obtained from the anterior cerebral artery and the superior sagittal
sinus, respectively. A structured method of visual assessment,
applying the semiquantitative ASPECTS technique, was used to
read the CTP maps. Areas showing normal CBV and MTT were
scored as 1 and those demonstrating an impairment as compared
to the contralateral hemisphere were rated as 0. ASPECTS
mismatch was defined as the CBV ASPECTS minus the MTT
ASPECTS. The ASPECTS mismatch is therefore a positive
ordinal scale ranging from 0 to 10. Images were read by two
trained assessors not involved in the acute care of the patients.
Follow-up NCCT was performed routinely at 24 h, or at any
time when a neurological deterioration occurred. The presence of
any intracerebral haemorrhage on follow-up imaging was
recorded.
Interventions
In accordance with the routine in-house clinical protocol, IS
patients presenting within 3 h of stroke onset who had an
ASPECTS $7 on NCCT and no contraindications to tPA were
thrombolysed. IS patients presenting between 3 and 6 h post onset
were eligible for thrombolysis if they had no contraindications to
tPA (apart from time), and demonstrated a target mismatch profile
defined as a CBV ASPECTS $7 and an ASPECTS mismatch
$2. Intravenous tPA (0.9 mg/kg, maximum 90 mg) was given as
an infusion over 60 min, with 10% of the total dose administered
as a bolus.
Analyses
Efficacy end-points included disability at 3 months, as assessed
by means of the mRS, with scores 0–2 indicating functional
independence, and 0–1 referring to minimal or no disability.
Another efficacy end-point was the change in the NIHSS score at
24 h. Safety end-points included overall mortality at 3 months,
any intracerebral haemorrhage (ICH), and SICH as defined
according to the SITS-MOST criteria [2].
Baseline characteristics, clinical outcome and ICHs were
compared between patients thrombolysed in the 0–3-h window
using NCCT and those treated at 3–6 h using CTP mismatch
criteria. Following the publication of the ECASS III trial [3],
groups of patients thrombolysed using CTP criteria in the 3–4.5-h
and 4.5–6-h windows were also compared. Comparisons were
undertaken with the t-test, Mann-Whitney U-test, chi-square or
Fisher exact test as appropriate. Odds ratios (OR) with 95%
confidence intervals (CI) were calculated for the outcome
measures. ORs adjusted for differences in baseline characteristics,
using logistic regression, are also reported. Stepwise logistic
regression modelling was performed to identify factors associated
with mRS 0–2 at 3 months in patients thrombolysed in the 3–6-h
window. Independent variables included age, sex, baseline NIHSS
score, blood pressure and OTT. The interactions between
age6OTT, NIHSS score6OTT and age6NIHSS score were
also examined. Inter-rater reliability was evaluated by using the
intraclass correlation coefficient derived from a 2-way random
effects model for absolute agreement. Two-sided p values are
reported, with the level of significance set at ,0.05. SPSS version
17.0 (SPSS Inc., USA) was used for analyses.
Results
Three hundred and nineteen thrombolysed IS patients with a
known time of onset and symptoms/signs attributable to MCA
involvement were entered into our database between January
2007 and December 2009. We excluded 24 patients in the 3–4.5-h
window who were thrombolysed without assessment of a CTP
mismatch, after the results of the ECASS III study had been
published [3]. We also excluded 41 patients in the 0–3-h time
window in whom CTP was performed with the purpose of
establishing a vascular cause of their symptoms (Figure S1). The
final analysis included 254 patients, of whom 174 (69%) were
thrombolysed at 0–3 h using NCCT, and 80 (31%) at 3–6 h using
CTP mismatch criteria. Of those thrombolysed at 3–6 h, 35 (44%)
were within 3–4.5 h and 45 (56%) between 4.5 and 6 h.
Baseline patient characteristics are compared in Table 1. The
median age was 74 years, and approximately half were male in
both groups. Atrial fibrillation was more common among those
treated at 0–3 h (43% v 30%, p=0.045). There was no significant
Stroke Thrombolysis at 3–6 h Using Perfusion CT
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ATT was 10 minutes longer in the 3–6-h group assessed with
CTP, a significant difference in comparison with the 0–3-h NCCT
group.
The rate of SICH was 3% in patients thrombolysed at 0–3 h
using NCCT, and 4% (p=0.61) among those in the 3–6 h
window receiving CTP (Table 2). There were no differences in
ICH, fatal ICH or mortality. The change in the median NIHSS
score at 24 h after thrombolysis (25v25, p=0.55) and the
proportion of patients with a favourable functional outcome
(mRS 0–2) at 3 months were comparable in the two groups (55%
v 54%, p=0.96) (Table 2, Figure 1). The OR for every outcome
remained statistically non-significant after adjustment for atrial
fibrillation and ATT. Comparisons between patients thrombo-
lysed at 3–4.5 h and those treated at 4.5–6 h revealed that more
older women were treated in the 4.5–6-h window, but there were
no differences in ICHs, mortality or other clinical outcomes
(Table 3).
A low baseline NIHSS score was the only independent
determinant of a favourable functional outcome (mRS 0–2) (OR
0.89, 95% CI 0.82–0.97, p=0.007) in patients treated using CTP
mismatch criteria beyond 3 h. There were no significant
interactions between NIHSS score, OTT or age.
The interobserver reliability scores for CBV, MTT and
mismatch ASPECTS were 0.82, 0.79 and 0.81, respectively
(p,0.0001 for each).
Discussion
This study demonstrates that SICH and the functional outcome
following thrombolysis of IS patients in the 3–6 h window using a
structured assessment of CTP mismatch are comparable to those
for patients thrombolysed at 0–3 h using NCCT alone. Within the
3–6-h group, there were no differences in SICH or functional
outcome between patients thrombolysed at 3–4.5 h and those
treated at 4.5–6 h, though the numbers in each group were
Table 1. Baseline characteristics and treatment times.
0–3 h NCCT (n=174) 3–6 h CTP mismatch (n=80) p value
Median age (year) 74 (65–82) 74 (62–81) 0.60
Male 92 (53%) 43 (54%) 0.90
Hypertension 118/173 (68%) 48 (60%) 0.20
Diabetes 35/173 (20%) 10 (13%) 0.14
Hypercholesterolaemia 55/167 (33%) 28/77 (36%) 0.60
Current smoker 33/154 (21%) 19/74 (26%) 0.47
Atrial fibrillation 74/171 (43%) 24 (30%) 0.045
Mean systolic BP (mmHg) 146 (126–166) 144 (122–166) 0.56
Mean diastolic BP (mmHg) 80 (66–94) 80 (66–94) 0.94
Mean baseline blood glucose (mmol/l) 7.1 (4.4–9.8) 6.8 (4.9–8.7) 0.43
Median baseline NIHSS 14 (9–19) 13 (7–18) 0.30
Median OTT (min) 120 (95–145) 280 (240–315) ,0.001
Median ATT (min) 60 (35–85) 70 (50–118) ,0.001
Data are median (interquartile range), number (%), or mean (61 standard deviation).
BP, blood pressure at baseline.
doi:10.1371/journal.pone.0025796.t001




mismatch (n=80) OR [95% CI] p value
Adjusted OR
[95% CI] p value
Haemorrhage
Any ICH 12/171 (7%) 7/79 (9%) 1.29 [0.49–3.41] 0.61 1.86 [0.67–5.16] 0.24
SICH 5/171 (3%) 3/79 (4%) 1.31 [0.31–5.63] 0.71 3.0 [0.59–15.21] 0.19
Fatal ICH 4/171 (2%) 0/79 0.31
Neurological function
Median 24 h NIHSS 7 (2–13) 6 (2–13) 0.93
Median change in NIHSS from baseline 25( 29t o22) 25( 28t o22) 0.55
Functional level at 3 months
mRS 0–1 69/157 (44%) 28/79 (35%) 0.70 [0.40–1.22] 0.21 0.63 [0.35–1.15] 0.14
mRS 0–2 86/157 (55%) 43/79 (54%) 0.99 [0.57–1.70] 0.96 0.93 [0.52–1.66] 0.81
mRS 6 (death) 25/160 (16%) 7/79 (9%) 0.53 [0.22–1.27] 0.15 0.77 [0.31–1.95] 0.58
Values in parentheses for Neurological function indicate interquartile range.
doi:10.1371/journal.pone.0025796.t002
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10 minutes to the ATT; however, this may not be clinically
disadvantageous as the OTT did not prove to be a significant
determinant of outcome among our patients exhibiting a CTP
mismatch in the 3–6-h window, a finding similarly observed in
studies using multimodal MR for patient selection [6,12]. Our
outcomes of late thrombolysis using CTP mismatch were
comparable to those of previous studies using MR mismatch
criteria [6,12].
There are some considerations concerning the use of CTP to
guide thrombolysis decisions in clinical settings. Image analysis
using thresholds for different CTP parameters and a quantitative
determination of mismatch volume may involve complicated
calculations frequently requiring additional software, which can
easily lead to significant delays in treatment. In contrast, the
semiquantitative ASPECTS methodology, originally designed for
the assessment of early ischaemic changes in the MCA territory on
NCCT, is a quick tool that has been applied to CTP too [13].
ASPECTS on CBV maps has been found to be a more accurate
predictor of irreversibly injured tissue and clinical outcome than
NCCT [13], with a good correlation to the DWI lesion on MRI
[14]. We believe that the CBV ASPECT threshold of $7 in our
study identified patients with a relatively small infarct core that is
associated with a more favourable prognosis [13]. The definition
of ASPECT mismatch was initially introduced in multimodal MRI
to facilitate mismatch assessment in a simple and reliable fashion,
without the need for time-intensive calculations [15]. The CBV
and MTT maps of CTP seem to provide a good estimate of the
extent of tissue at risk [13], which can also be expressed as an
ASPECT mismatch score. A CTP ASPECT mismatch score of
$2, as used in our penumbral model for patient selection, has
been found to be the optimum cut-off point for a volumetric
mismatch of $100% [16]. The previously reported excellent
interrater reliability for ASPECT scoring of CTP maps was
likewise confirmed by our study [13]. We therefore conclude that a
rapid structured assessment of mismatch on CTP maps has the
potential to reliably guide thrombolytic treatment in IS patients in
an extended time window. However, we are aware of concerns
regarding the CTP technique itself, inclusive of limited brain
coverage, the lack of clearly defined thresholds for salvageable
tissue, and the variability of results depending on the type of
postprocessing software, highlighting the need for validation and
standardization of CTP methods [8,17].
There are some limitations to this study. Although the case
numbers in this single centre were obviously lower than in
multicentre registries, they compare very well with those in studies
of similar design looking at multimodal MRI-guided thrombolysis
in an extended time window [12]. A potential further limitation is
Table 3. Comparison of patients treated in the 3–4.5-h and 4.5–6-h windows using CTP mismatch.
3–4.5 h (n=35) 4.5–6 h (n=45) p value
Baseline characteristics
Median age (year) 69 (51–78) 74 (65–80) 0.023
Male 24 (69%) 19 (42%) 0.019
Hypertension 17 (49%) 31 (69%) 0.066
Diabetes mellitus 5 (14%) 5 (11%) 0.74
Hypercholesterolaemia 11/32 (34%) 17 (38%) 0.76
Current smoker 12/33 (36%) 7/41 (17%) 0.059
Atrial fibrillation 8 (23%) 16 (36%) 0.22
Mean systolic BP (mm Hg) 144 (119–169) 145 (127–163) 0.81
Mean diastolic BP (mm Hg) 79 (64–94) 81 (68–94) 0.61
Mean baseline blood glucose (mmol/l) 6.7 (4.5–8.9) 6.8 (5.0–8.6) 0.99
Median baseline NIHSS 11 (7–18) 13 (8–18) 0.38
Median OTT (min) 230 (197–243) 310 (285–330) ,0.001
Outcome measures
Any ICH 2/34 (6%) 5 (11%) 0.69
SICH 1/34 (3%) 2 (4%) 1.00
Fatal ICH 0/34 (0%) 0 (0%)
Median 24-h NIHSS 4 (2–10) 7 (3–13) 0.39
Median change in NIHSS from baseline 25( 28t o22) 25( 28t o21) 0.91
mRS 0–1 at 3 months 12/34 (35%) 16 (36%) 0.98
mRS 0–2 at 3 months 20/34 (59%) 23 (51%) 0.50
mRS 6 (death) at 3 months 5/34 (15%) 2 (4%) 0.13
Data are median (interquartile range), number (%), or mean (61 standard deviation).
BP, blood pressure at baseline.
doi:10.1371/journal.pone.0025796.t003
Figure 1. Distribution of scores on the mRS.
doi:10.1371/journal.pone.0025796.g001
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Results from the Diffusion and Perfusion Imaging Evaluation for
Understanding Stroke Evolution (DEFUSE) study, however,
suggest that early reperfusion is not beneficial in patients with a
‘no mismatch’ profile [7]. Moreover, there were no non-
thrombolysed controls with a mismatch profile, and we are
unaware of a single placebo-controlled study of intravenous tPA
treatment of patients exhibiting a mismatch on CTP. As the results
of the ECASS III trial became available only towards the end of
our study period [3], it was not a pre-defined objective of this
investigation to include patients treated by using only a NCCT in
the 3–4.5-h window. Since this was an open study, outcomes may
have been assessed more favourably in the 3–6-h group. Although
this could potentially have affected NIHSS and mRS assessments,
neither mortality nor the detection of a haemorrhage on CT were
subject to this bias. The results of this study can be generalized to
patients with a stroke in the anterior circulation. Those with
symptoms in the posterior circulation, a territory where CTP is
known to underperform, were excluded.
A recent meta-analysis of mismatch-based thrombolysis after
3 h of stroke onset, including trials of desmoteplase in a significant
proportion, did not demonstrate an improvement in clinical
outcome, despite increased reperfusion [18]. This is in contrast
with the conclusions of multimodal MRI-based cohort studies of
tPA and also of our own investigation [6,12]. The ongoing phase
III randomised controlled Extending the Time for Thrombolysis
in Emergency Neurological Deficits (EXTEND) study is expected
to explore the benefit of multimodal MRI-based tPA treatment in
the 3–9-h window [19], and we propose that similar trials using
CTP mismatch criteria are also warranted, with a potential to
nearly double the number of IS patients receiving thrombolysis
[20].
Supporting Information
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(PDF)
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